OM Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -86.66% compared to Outset Medical's net margin of --. Outset Medical's return on equity of -140.06% beat Perspective Therapeutics's return on equity of --.

Outset Medical has a consensus price target of $24.50, signalling upside risk potential of 35.36%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 245.76%. Given that Perspective Therapeutics has higher upside potential than Outset Medical, analysts believe Perspective Therapeutics is more attractive than Outset Medical.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Outset Medical's net income of -$25.8M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Outset Medical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.68x versus 28.76x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies has a net margin of -86.66% compared to Outset Medical's net margin of -19.35%. Outset Medical's return on equity of -140.06% beat iRhythm Technologies's return on equity of -112.03%.

Outset Medical has a consensus price target of $24.50, signalling upside risk potential of 35.36%. On the other hand iRhythm Technologies has an analysts' consensus of $145.67 which suggests that it could grow by 6.33%. Given that Outset Medical has higher upside potential than iRhythm Technologies, analysts believe Outset Medical is more attractive than iRhythm Technologies.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.413, suggesting its more volatile than the S&P 500 by 41.267%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are smaller than iRhythm Technologies quarterly revenues of $158.7M. Outset Medical's net income of -$25.8M is higher than iRhythm Technologies's net income of -$30.7M. Notably, Outset Medical's price-to-earnings ratio is -- while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.68x versus 6.94x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -86.66% compared to Outset Medical's net margin of -2201.34%. Outset Medical's return on equity of -140.06% beat VolitionRX's return on equity of --.

Outset Medical has a consensus price target of $24.50, signalling upside risk potential of 35.36%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 320%. Given that VolitionRX has higher upside potential than Outset Medical, analysts believe VolitionRX is more attractive than Outset Medical.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are larger than VolitionRX quarterly revenues of $246.4K. Outset Medical's net income of -$25.8M is lower than VolitionRX's net income of -$5.4M. Notably, Outset Medical's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.68x versus 48.25x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -86.66% compared to Outset Medical's net margin of 0.18%. Outset Medical's return on equity of -140.06% beat Xtant Medical Holdings's return on equity of -26.62%.

Outset Medical has a consensus price target of $24.50, signalling upside risk potential of 35.36%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Xtant Medical Holdings has higher upside potential than Outset Medical, analysts believe Xtant Medical Holdings is more attractive than Outset Medical.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Outset Medical's net income of -$25.8M is lower than Xtant Medical Holdings's net income of $58K. Notably, Outset Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.68x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.